Black Friday saleUp to 70% OFF

ABBOTINDIA

Abbott India Poised for Upside: Targets ₹29,360Abbott India closed the week at ₹28,808, showing signs of strength as it approaches key upside targets of ₹29,360 and ₹29,800. With RSI above 50%, the stock is signaling increased bullish momentum, making it an attractive buy for the upcoming week. The stock has recently corrected over 10% during the previous downturn, creating an opportunity for a rebound. Investors looking for a return of over 3% may find this an ideal entry point. The major support level is at ₹28,093, providing a solid foundation for any potential pullbacks. As long as the stock remains above this support and RSI continues to stay above 50, the bullish trend is expected to persist. This setup offers a favorable risk-reward ratio, making it a great opportunity for those looking to capitalize on Abbott India’s upside potential next week.
NSE:ABBOTINDIALong
by Sudhir-Sirohi
Abbott India Ltd. (ABBOTIND) StrategyThe chart is a 4-hour candlestick chart of Abbott India Ltd. (ABBOTIND) on the NSE, with the current price at INR 26,196.20. The chart illustrates a symmetrical triangle pattern, highlighting key support and resistance levels and suggesting potential trade strategies based on price movements. Key Observations: 1. Current Price and Trend: - The current price is INR 26,196.20, reflecting an increase of 1.08%. - The price is currently near the lower boundary of the symmetrical triangle. 2. Support and Resistance Levels: - Immediate support is at INR 25,000. - The next significant support level is at INR 23,591. - Resistance levels include INR 26,700 and INR 27,100. 3. Symmetrical Triangle Pattern: - The chart shows a symmetrical triangle pattern, indicating a potential breakout in either direction. - Traders are watching for a breakout above the upper trendline or a breakdown below the lower trendline. 4. Trade Strategies: - Buy Strategy: - If the price breaks above INR 27,100, it signals a potential bullish breakout. - Traders could buy at the breakout level or wait for a retracement and buy at INR 26,700. - The target for this buy strategy is INR 28,700. - Sell Strategy: - If the price breaks below INR 25,000, it signals a potential bearish breakout. - Traders could sell at the breakdown level or wait for a retracement and sell at INR 26,000. - The target for this sell strategy is INR 23,600. Summary: The chart suggests a symmetrical triangle pattern for Abbott India Ltd., with the current price positioned near the lower boundary of the triangle. Key support is at INR 25,000, with further support at INR 23,591, while resistance levels are at INR 26,700 and INR 27,100. Traders are advised to watch for a breakout above INR 27,100 to initiate a buy with a target of INR 28,700 or a breakdown below INR 25,000 to initiate a sell with a target of INR 23,600. The decision to enter trades can also be based on waiting for retracement levels to ensure stronger confirmation of the breakout or breakdown.
NSE:ABBOTINDIA
by The90sTraderOfficial
1
Abbott Laboratories (ABT) Navigating Earnings Abbott Laboratories ( NYSE:ABT ) recently reported earnings that slightly missed expectations at the midpoint, causing a 3.3% dip in NYSE:ABT stock to $110.21. However, a closer look at the results reveals a more nuanced story. Despite the earnings guidance falling short by three pennies at $4.60 per share for the year, the health care giant remains resilient, projecting a robust 8% to 10% organic sales growth. Investors should pay attention as NYSE:ABT stock forms a saucer base with a potential buy point at $115.83. Strong Growth in Medical Devices: One of the key drivers behind Abbott's solid performance was the outstanding growth in its medical devices segment. Sales in this category surged 15.4% organically to $4.44 billion. Notably, the diabetes division played a significant role, with revenues reaching $1.55 billion, marking a substantial 20.7% increase. The star performer in this space was Abbott's body-worn glucose monitor, FreeStyle Libre, which contributed $1.4 billion in sales, up by an impressive 23.8% on an organic basis. Electrophysiology Segment Shines: Another highlight for Abbott ( NYSE:ABT ) was the electrophysiology segment, where revenue grew 15.9% organically to nearly $2.2 billion. This growth is particularly noteworthy considering the challenges posed by a new technology called pulsed field ablation (PFA), which is emerging in the electrophysiology testing space. Analysts believe that Abbott's robust performance in this segment allays fears of losing market share to PFA, underscoring the company's adaptability and resilience. Rapid Diagnostics Faces Headwinds: While Abbott ( NYSE:ABT ) celebrated success in medical devices and electrophysiology, the rapid diagnostics segment faced headwinds. Excluding Covid tests, sales declined by 13.7% to $862 million. The decline was attributed to a later-than-expected flu season, with cases spiking in January. Despite this setback, core lab sales managed to climb 9.7% to $1.37 billion, showcasing the diversified portfolio and the ability to navigate challenges. Conclusion: Abbott Laboratories' ( NYSE:ABT ) recent earnings report might have initially disappointed investors, but a deeper analysis reveals a company that is strategically positioned for growth. With a saucer base forming and a potential buy point at $115.83, savvy investors may see this dip in NYSE:ABT stock as a buying opportunity. Abbott's ability to innovate in the medical devices space, navigate challenges in rapid diagnostics, and shine in electrophysiology suggests that the company is well-poised for sustained success in the dynamic healthcare industry.
NYSE:ABT
by DEXWireNews
ABBOTINDIA - Breakout after consolidation - SwingThis analysis is done purely on basis of price action and chart patterns. The analysis is done on weekly TF hence it can take couple of weeks to reach the target. But as the stock is in bullish trend on longer TF, it may reach target within few days as well. Trade Logic, SL and Target is shown in image itself. Daily TF chart is attached below for reference. This analysis is for study purpose. Traders must do their own study before entering into any trade. Traders should trade with their own risk capacity and money management. Feel Free to comment for any query or suggestion regarding this stock or Price Action Analysis
NSE:ABBOTINDIALong
by AdityaKarn90